Answers are grounded in this paper and cite their sources.
All together, these data support that third-generation, EGFRvIII-specific mCARs are effective against gliomas in the brain and highlight the importance of syngeneic, immunocompetent models in the preclinical evaluation of tumor immunotherapies.
No takes yet. Share an insight, caveat, or question.
Sampson et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: